Affordable Access

Carboplatin in the treatment of ovarian cancer

Authors
Journal
Seminars in Oncology
0093-7754
Publisher
Elsevier - WB Saunders
Publication Date
Keywords
  • Carboplatin (Jm-8
  • Cbdca) A New Platinum Compound
Disciplines
  • Medicine

Abstract

Abstract Carboplatin, a new cisplatin analogue, appears as active as cisplatin in patients with advanced ovarian cancer, but in phase I and II trials has proven significantly less toxic. In single-agent phase II trials, carboplatin has been associated with clinical complete response (CR) rates of up to 13% and overall objective response rates of up to 32% in patients with prior cisplatin exposure. As first-line treatment in phase II trials, single-agent carboplatin has produced clinical CR rates ranging from 9% to 62% and overall objective response rates of 45% to 85%. In phase III trials in this patient population, single-agent carboplatin has been associated with clinical CR rates comparable with or exceeding those of single-agent cisplatin. Phase I/II trials of combination chemotherapy have yielded overall objective response rates of 44% to 75% when carboplatin was combined with either cyclophosphamide or chlorambucil. In randomized phase III trials of combination chemotherapy, response rates similar to those of cisplatin have been achieved. However, toxicities were greatly reduced in the carboplatin-treated patients. The data from these phase I, II, and III trials document that carboplatin is as active as cisplatin in patients with advanced ovarian cancer and is associated with a significantly lower incidence of emesis, ototoxicity, peripheral neuropathy, and renal dysfunction. Thus, carboplatin may become the platinum compound of choice in the first-line treatment of advanced ovarian cancer.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Carboplatin in the treatment of ovarian cancer.

on Seminars in Oncology April 1989

Paclitaxel plus carboplatin in the treatment of ov...

on Seminars in Oncology February 1999

New developments with carboplatin in the treatment...

on Seminars in Oncology Jan 01, 1992
More articles like this..